Atlas Trials

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

Clinical trial NCT03278665 · COMPLETED

Trial details

NCT number
NCT03278665
Sponsor
4SC AG
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2017-09-25
Primary completion
2022-02-02
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.